Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Fineline Cube Aug 21, 2026
Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Fineline Cube Aug 21, 2026
Policy / Regulatory

NMPA Strengthens Oversight of COVID-19 Drugs and Home Treatment Guidelines

Fineline Cube Jan 5, 2023

The National Medical Products Administration (NMPA) has released a notification aimed at enhancing the quality...

Company Medical Device

NMPA Approves Chinabridge’s ECMO Equipment for Emergency Use

Fineline Cube Jan 5, 2023

The National Medical Products Administration (NMPA) has approved Chinabridge (Shenzhen) Medical Technology Co., Ltd’s extracorporeal...

Company Drug

EOC Pharma’s Entinostat NDA Accepted by China’s NMPA for Breast Cancer

Fineline Cube Jan 5, 2023

EOC Pharma, a biotech company operating in the US and China, has announced that its...

Company Deals

HighTide Therapeutics Completes $107 Million Series C and C+ Financing Rounds

Fineline Cube Jan 5, 2023

China-based HighTide Therapeutics Inc. has announced the completion of Series C and C+ financing rounds,...

Company Deals R&D

Biogen and Tsinghua University Launch Three-Year Neuroscience Collaboration

Fineline Cube Jan 5, 2023

US-based Biogen (NASDAQ: BIIB) and the School of Pharmaceutical Sciences at Tsinghua University have announced...

Policy / Regulatory

China’s NHC and NATCM Launch Integrated Pain Management Pilot Plan

Fineline Cube Jan 5, 2023

The National Health Commission (NHC) and the National Administration of Traditional Chinese Medicine (NATCM) have...

Company Deals

Zhongchao Partners with Natco Pharma to Distribute Drugs in China

Fineline Cube Jan 5, 2023

Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced multiple agreements with...

Company Deals

By-Health to Establish Nutrition Research Center with Shanghai Institute

Fineline Cube Jan 5, 2023

China-based By-Health Co., Ltd. (SHE: 300146) is set to establish a “scientific nutrition research and...

Company Deals

CANbridge Secures Global Rights to Second-Generation Gene Therapy for SMA

Fineline Cube Jan 4, 2023

China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to...

Company Drug

Transcenta’s TST003 Receives Clinical Trial Approval in China and US

Fineline Cube Jan 4, 2023

China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received...

Company Drug

Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications

Fineline Cube Jan 4, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline

Fineline Cube Jan 4, 2023

China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion...

Company Drug

HutchMed Completes Enrollment for Phase III ESLIM-01 Study of Sovleplenib in ITP

Fineline Cube Jan 4, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment...

Company Drug

RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer

Fineline Cube Jan 4, 2023

China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received...

Company Deals

Apeloa and Simcere Partner for CDMO Services and R&D Collaboration

Fineline Cube Jan 4, 2023

China – based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739)...

Company Deals

Sino Biopharmaceutical’s CTTQ Partners with ProteLight for Antibacterial Peptide PL-5

Fineline Cube Jan 4, 2023

China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia...

Company Deals

Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds

Fineline Cube Jan 4, 2023

Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully...

Company

Everest Medicines Outlines Strategic Plans for Expansion and Growth

Fineline Cube Jan 4, 2023

China – based biopharmaceutical company Everest Medicines (HKG: 1952) has announced its strategic plans for...

Company

Zai Lab Appoints Dr. Rafael Amado as President of Cancer R&D

Fineline Cube Jan 4, 2023

Chinese biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the appointment of...

Company Drug

Jiangxi Jemincare Gains FDA Approval for Clinical Trial of JYB1907 in Solid Tumors

Fineline Cube Jan 4, 2023

China – based Jiangxi Jemincare Group has announced that it has received approval from the...

Posts pagination

1 … 623 624 625 … 711

Recent updates

  • CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors
  • LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval
  • China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect
  • Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health
  • Ultomiris Wins NMPA Approval for PNH in China, Bringing Long‑Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Company

Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.